Lucid Diagnostics Inc. (LUCD) Stock Price & Analysis

Lucid Diagnostics Inc. (LUCD) fell 1.23% to USD 0.94 as of September 8, 2026 at 09:03 UTC, according to Nexqual real-time market data.

LUCD last closed at USD 0.94; the session ranged USD 0.93–0.96 on volume of 1,016,800 shares. Market capitalization is —, with a 52-week range of USD 0.86–1.63 (NCM). Source: Nexqual, September 8, 2026 at 09:03 UTC.

Key Statistics (as of September 8, 2026 at 09:03 UTC)

Technical Analysis (LUCD)

Nexqual's technical model rates LUCD "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 09:03 UTC.

From Lucid Diagnostics Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Subsequent to December 31, 2025, as of March 23, 2026, the Company sold 4,161,747 shares through its at-the-market equity facility for net proceeds of approximately $5.3 million, after payment of 3% commissions.   8 Table of Contents Intellectual Property   Our business will depend on proprietary medical device and diagnostic technologies, including the EsoCheck and EsoGuard technology licensed by us.
• Pursuant to this designa tion, we will be working with FDA to submit the premarket submission for EsoGuard.   Before and after approval or clearance in the United States, our products are subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act and/or the Public Health Service Act, as well as by other regulatory bodies.
• We intend to vigorously protect our proprietary technologies' intellectual property rights in patents, trademarks and copyrights, as available through registration in the United States and internationally.
• We protect our proprietary rights through a variety of methods, including confidentiality agreements and/or proprietary information agreements with suppliers, employees, consultants, independent contractors and other entities who may have access to proprietary information.

Partnerships

• PAVmed's substantial voting interest may discourage a change of control that other holders of our common stock may favor.   We are party to a management services agreement with PAVmed (the "MSA"), as well as a payroll benefits and expense reimbursement agreement (the "PBERA").
• The Company intends to use the net proceeds from the September 2025 Offering for working capital and other general corporate purposes.   ATM Facility        On May 30, 2025, the Company entered into an "at-the-market offering" ("ATM") for up to $25.0 million of its common stock that may be offered and sold under a Controlled Equity Offering Agreement between the Company and Maxim Group LLC.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:03 UTC. This page is informational and not investment advice.